A Phase 1, Open‑Label Fixed‑Sequence 2‑Period Crossover Study Of Palbociclib (pd‑0332991) In Healthy Volunteers To Estimate The Effect Of Antacid Treatment On The Bioavailability Of A 125 Mg Single Dose Of Six Experimental Formulations Of Palbociclib Relative To Palbociclib Administration Alone Under Fasted Conditions

Trial Profile

A Phase 1, Open‑Label Fixed‑Sequence 2‑Period Crossover Study Of Palbociclib (pd‑0332991) In Healthy Volunteers To Estimate The Effect Of Antacid Treatment On The Bioavailability Of A 125 Mg Single Dose Of Six Experimental Formulations Of Palbociclib Relative To Palbociclib Administration Alone Under Fasted Conditions

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2015

At a glance

  • Drugs Palbociclib (Primary) ; Rabeprazole
  • Indications Breast cancer; Colorectal cancer; Glioblastoma; Liposarcoma; Malignant melanoma; Mantle-cell lymphoma; Non-small cell lung cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 14 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 17 Feb 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
    • 13 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top